2022 Pharmacy Survey Results: Aduhelm | Part 5

August 22, 2022

The respondents were almost evenly split on whether it was a mistake for the FDA to approve Aduhelm, but a large majority agreed that CMS made the right decision to restrict Medicare coverage to those enrolled in clinical trials.

2022 Pharmacy Survey Results: COVID-19 | Part 1

August 16, 2022

Our survey shows some optimism about the course of the COVID-19 pandemic, but concern about Paxlovid rebound. Former President Donald Trump’s job performance on COVID-19 was rated low while the World Health Organization and Pfizer were rated high.

Zynteglo May Herald “New Dawn” of Many Seven-Figure Gene Therapies

August 05, 2022

An OptumRx drug pipeline report highlights Zynteglo, a curative gene therapy treatment for beta-thalassemia, and Skysona, a gene therapy for a cerebral adrenoleukodystrophy. FDA approval decision are imminent for both. Price tags of $2 million are expected.

FTC Has Put PBMs, PBM Rebates in its Hot Seat

June 17, 2022

A week after announcing a study of the PBM industry, the Federal Trade Commission announced yesterday that it was stepping up possible enforcement actions targeting the industry's rebate practices. Rebates to exclude lower costs from formularies may constitute commercial bribery under the Robinson-Patman Act, the commission said.